LONG-TERM RESULTS OF HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE FOR HIGH-RISK NEUROBLASTOMA PATIENTS: A Report of the Spanish Working Party for BMT in Children (GETMON)

REFERENCES

• Philip T, Zucker J M, Bernard J L, et al, Improved survival at 2 years and 5 years in the LMCE1 un-selected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup?. J Clin Oncol. 1991; 9: 1037–1044. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Campbell L A, Seeger R C, Harris R E. Escalating dose of continuous infusion combination chemotherapy for refractory neu-roblastoma. J Clin Oncol. 1993; 11: 623–629. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Frappaz D, Michon J, Coze C, et al, LMCE3 treatment strategy: results in 99 consecutively diagnosed stage IV neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol. 2000; 18: 468–476. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Katzenstein H M, Cohn S L. Advances in the diagnosis and treatment of neuroblastoma. Curr Opin Oncol. 1998; 10: 43–51. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Matthay K K. Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant. 1996; 18(suppl 3)521–524
   PubMedGoogle Scholar
• Cheung NK V, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991; 9: 1050–1058. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kletzel M, Katzenstein H M, Haut P R, et al, Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002; 9: 2284–2292
   Google Scholar
• Pinkerton C R. ENSG-1-Randomized study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant. 1991; 7(suppl 3)112–113. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Matthay K K, Villablanca J G, Seeger R C, et al, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. New Engl J Med. 1999; 341: 1165–1173. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Seeger R C, Reynolds C P. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am. 1991; 38: 393–424. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Matthay K K, Seeger R C, Reynolds C P, et al, Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol. 1994; 12: 2382–2389. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Pardo N, Marti F, Fraga G, et al, High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol. 1996; 27: 531–539
   Google Scholar
• Brodeur G M, Seeger R C, Banet A, et al, International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol. 1998; 6: 1874–1881
   Google Scholar
• Brodeur G M, Pritchard J, Berthold F, et al, Revisions of the International Criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993; 11: 1466–1477. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Castel V, Garcia-Miguel P, Canete A, et al, Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. Eur J Cancer. 1999; 35: 606–611. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Castel V, Garcia-Miguel P, Melero A, et al, The treatment of advanced neuroblastoma: results of the Spanish Neuroblastoma Study Group (SNSG) studies. Eur J Cancer. 1995; 31A: 642–645. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Castel V, Cañete A, Navarro S, et al, Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol. 2001; 37: 537–542. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Gorin N C, Aergerter P, Auvert B, et al, Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood. 1990; 75: 1606–1614. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Canals C, Punti C, Picón M, et al, Immunomagnetic purging in autologous bone marrow transplantation: experience in fourteen patients. Prog Clin Biol Res. 1992; 377: 289–296. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Mora J, Gerald W L, Qin J, Cheung N-K V. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. Cancer. 2002; 94: 2756–2765. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cohn S L, Moss T J, Hoover M, et al, Treatment of poor-risk neuroblastoma with high-dose chemotherapy and autologous stem cell rescue. Bone Marrow Transplant. 1997; 20: 543–551. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Garaventa A, Rondelli R, Lanino F, et al, Myeloablative therapy and bone marrow rescue in advanced neuroblastoma: report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology BMT Group. Bone Marrow Transplant. 1996; 18: 125–130. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Philip T, Ladenstein R, Lasser C, et al, 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. EGBMT Registry Solid Tumors Working Party. Eur J Cancer. 1997; 33: 2130–2135. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Rill D R, Santana V B, Roberts W M, et al, Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994; 84: 380–383. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Grupp S A, Ster J W, Bunin N, et al, Tandem high-dose therapy rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000; 18: 2567–2575. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kanold J, Yakouben K, Tchirkov A, et al, Long-term results of CD34+ cell transplantation. Med Pediatr Oncol. 2000; 35: 1–7. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Burchill S A, Lewis I J, Abrams K R, et al, Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol. 2001; 19: 1795–1801. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Villablanca J G, Khann A A, Avramis V I, et al, Phase I trial of 13-cis-retinoic acid children with neuro-blastoma following bone marrow transplantation. J Clin Oncol. 1995; 13: 894–901. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Michon J, Negrier S, Coze C, et al, Administration of high dose interleukin-2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseilles-Curie-East of France Group Study. Prog Clin Biol Res. 1994; 385: 293–300. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Rueda F, Marti F, Pardo N, et al, Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies. Cancer Biother Radiopharm. 1996; 11: 303–308. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Sangthawan D, DesRosiers P M, Randall M E, et al, Relapse in the skull after myeloablative therapy for high-risk neuroblastoma. Pediatr Hematol Oncol. 2003; 20: 23–30. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar